Overview

Palliative Thoracic Radiotherapy Plus BKM120

Status:
Completed
Trial end date:
2017-10-17
Target enrollment:
Participant gender:
Summary
This study will test whether a drug called BKM120/buparlisib is a safe and effective treatment when given to lung cancer patients having radiotherapy treatment. The trial will identify which of three possible doses of buparlisib is best to give with lung radiotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
University of Oxford
Collaborators:
Cancer Research UK
Novartis